Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational PK study assessing ANEB001 in patients presenting to Emergency Departments with cannabis toxicity

Next Previous
Trial Profile

Observational PK study assessing ANEB001 in patients presenting to Emergency Departments with cannabis toxicity

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selonabant (Primary)
  • Indications Substance-related disorders
  • Focus Pharmacokinetics

Most Recent Events

  • 06 Feb 2026 According to an Anebulo Pharmaceuticals media release, this trial is being amended to focus on pediatric patients.
  • 26 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top